Must-pass user fee deals: Biopharma companies fund more than 80% of FDA's review staff, CDER head tells Congress
Every five years, the FDA and biopharma industries negotiate an agreement explaining how much the companies will need to pay in so-called user fee funds, as well as what goals the FDA has to meet in its product reviews.
But even after those agreements have been hashed out, Congress still has to authorize the user fee agreements sometime before the current agreements expire in September.
The House Energy & Commerce subcommittee on health held a hearing on the re-authorizations Thursday, and representatives on both sides of the aisle expressed agreement on the importance of the timely reauthorization of these user fees.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.